UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

o

Rule 13d-1(b)

x

Rule 13d-1(c)

o

Rule 13d-1(d)

CUSIP No. 89235K105

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
GIMV, NV

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

o

(b)

x

3.

SEC Use Only

4.

Citizenship or Place of Organization
Belgium

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0

6.

Shared Voting Power
2,628,603

7.

Sole Dispositive Power
0

8.

Shared Dispositive Power
2,628,603

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
2,628,603

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

11.

Percent of Class Represented by Amount in Row (9)
16.34%

12.

Type of Reporting Person (See Instructions)
CO

CUSIP No. 89235K105

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Adviesbeheer GIMV Life Sciences, NV

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

o

(b)

x

3.

SEC Use Only

4.

Citizenship or Place of Organization
Belgium

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0

6.

Shared Voting Power
2,628,603

7.

Sole Dispositive Power
0

8.

Shared Dispositive Power
2,628,603

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
2,628,603

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

11.

Percent of Class Represented by Amount in Row (9)
16.34%

12.

Type of Reporting Person (See Instructions)
CO

CUSIP No. 89235K105

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Biotech Fonds Vlaanderen, NV

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

o

(b)

x

3.

SEC Use Only

4.

Citizenship or Place of Organization
Belgium

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0

6.

Shared Voting Power
2,628,603

7.

Sole Dispositive Power
0

8.

Shared Dispositive Power
2,628,603

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
2,628,603

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

11.

Percent of Class Represented by Amount in Row (9)
16.34%

12.

Type of Reporting Person (See Instructions)
CO

CUSIP No. 89235K105

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Patrick Van Beneden, Executive Vice President, Life Sciences

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

o

(b)

x

3.

SEC Use Only

4.

Citizenship or Place of Organization
Belgium

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0

6.

Shared Voting Power
2,628,603

7.

Sole Dispositive Power
0

8.

Shared Dispositive Power
2,628,603

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
2,628,603

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

11.

Percent of Class Represented by Amount in Row (9)
16.34%

12.

Type of Reporting Person (See Instructions)
CO

Item 1.

(a)

Name of Issuer
TorreyPines Therapeutics, Inc.

(b)

Address of Issuer’s Principal Executive Offices
11085 North Torrey Pines Road, Suite 300

La Jolla, CA  92037

Item 2.

(a)

Name of Person Filing
GIMV, NV

(b)

Address of Principal Business Office or, if none, Residence
Karel Oomsstraat 37

B-2018 Antwerpen, Belgium

(c)

Citizenship

(d)

Title of Class of Securities

(e)

CUSIP Number

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

o

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)

o

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)

o

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)

o

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

(e)

o

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)

o

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)

o

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

o

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

o

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

o

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Not applicable, this statement is filed pursuant to 13d-1(c).

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount beneficially owned:   

2,628,603 (see schedule below by fund)

(b)

Percent of class:   

16.34%

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote   

0

(ii)

Shared power to vote or to direct the vote    

2,628,603

(iii)

Sole power to dispose or to direct the disposition of   

0

(iv)

Shared power to dispose or to direct the disposition of   

2,628,603

Entity Name

Common Stock

Warrants for
Common
Stock

Total Shares
Beneficially
Owned

Beneficial
Ownership
%

GIMV NV

1,544,403

286,897

1,831,300

Adviesbeheer GIMV Life Sciences, NV

193,776

35,782

229,558

Biotech Fonds Vlaanderen, NV

477,704

90,041

567,745

Total GIMV NV combined holdings:

2,215,883

412,720

2,628,603

16.34

%

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following o.

N/A

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

N/A

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

N/A

Item 8.

Identification and Classification of Members of the Group

N/A

Item 9.

Notice of Dissolution of Group

N/A

Item 10.

Certification

By signing  below I certify  that,  to the best of my  knowledge  and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or  influencing the control of the issuer of the  securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

February 14, 2007

(Date)

GIMV

By: /s/ Dirk Boogmans

Name: Dirk Boogmans

Title:   President & Chief Executive Officer

By: /s/ Dirk Beeusaert

Name: Dirk Beeusaert

Title:   Chief Legal Officer